Background
Human growth hormone is an anabolic agent that attenuates injury-induced catabolism and stimulates protein synthesis. Recombinant human growth hormone (rhGH) administered therapeutically to patients with massive burns has been shown to increase the rate of skin graft donor site healing. It has been postulated that growth hormone affects wound healing and tissue repair by stimulating the production of insulin-like growth factor-1 (IGF-1) by the liver to increase circulating IGF-1 concentrations. The mechanism by which it improves wound healing, however, remains in question. The authors hypothesize that rhGH up-regulates IGF-1 receptors and IGF-1 levels both systemically and locally in the wound site to stimulate cell mitosis and increase synthesis of laminin, collagen types IV and VII, and cytokeratin. This hypothesis was tested in nine patients with burns covering >40% of total body surface area.
Objective
The authors assessed the efficacy of rhGH in promoting several major building materials in the donor site of patients with massive burns.
Methods
Ten massively burned patients with full-thickness burns covering more than 40% of total body surface area were participants in a placebo-controlled prospective study to determine the efficacy of 0.2 mg/kg/day rhGH on donor site wound healing and to identify some of the major components involved in wound healing and its integrity.
Results
Donor sites in burn patients receiving rhGH showed an increased coverage by the basal lamina of 26% for placebo to 68% coverage of the dermal-epidermal junction. Insulin-like growth factor-1 receptors and laminin, types IV and VII collagen, and cytokeratin-14 all increased significantly. Healing times of the donor sites were significantly decreased compared with patients receiving placebo.
Conclusion
Results indicate that growth hormone or its secondary mediators may directly stimulate the cells of the epidermis and dermis during wound healing to produce the structural proteins and other components needed to rebuild the junctional structures.
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Herndon and Others Human growth hormone has been shown to be an anabolic agent that attenuates injury-induced catabolism, stimulates protein synthesis and immune function, and increases muscle mass."'4 Recombinant human growth hormone (rhGH) administered therapeutically to massively burned patients has been shown to increase the rate of skin graft donor site healing by 20% to 30%, resulting in a 25% to 35% reduction in the length of hospital stay.5,6 It has been postulated that growth hormone affects wound healing and tissue repair by stimulating the production ofinsulin-like growth factor-1 (IGF-1) by the liver to increase circulating IGF-1 concentrations. 7-"' However, the mechanism by which it improves wound healing remains in question. We hypothesize that rhGH up-regulates IGF-1 receptors and IGF-1 levels both systemically and locally in the wound site to stimulate cell mitosis and increase laminin, collagen types IV and VII, and cytokeratin synthesis. This hypothesis was tested in nine patients with burns covering >40% of total body surface area.
METHODS
The ten patients selected for study ranged from 6 to 30 years of age, with full-thickness burns covering more than 40% of total body surface area. All patients were resuscitated by a standard formula, with intravenous fluids administered to maintain a urinary output of 0.5 to 1.0 mL/kg/hour. Electrolyte supplementation was given to achieve appropriate serum concentrations,12 and nutritional support was given enterally at 6300 kJ/ m 2/body surface area/day plus 6300 kJ/m2/total body surface area burn/day. 13-15 One of two surgeons excised and grafted the burn wound, excluding the face and perineum, within 48 hours of admission. Donor sites were harvested using a Padgett electric dermatome (Padgetts Instruments, Kansas City, MO) set at 0.010 inches and dressed with Scarlet Red (Sherwood Medical, St. Louis, MO) impregnated fine mesh gauze. From the third postoperative day, the donor site was examined by one of two evaluators blinded to the treatments. Using sterile technique, each corner of the gauze was gently lifted, using forceps to determine the adherence of the dressing to the underlying tissue. Any unattached dressing was trimmed away. This procedure was repeated daily until the gauze no longer adhered to the underlying wound. Healing time was defined as the time, in days, for the first For electron microscopy studies, 0.5-,tm-thick sections were stained with toluidine blue to identify the areas of interest; and ultrathin (70-nm) sections were prepared using a diamond knife and stained with uranium acetate and lead citrate. Electron micrographs were prepared at constant magnification to include all of the dermal-epidermal junction seen using a single specimen grid. On 8 X 10" prints, the dermal-epidermal junction was marked, and the lamina densa of the basal lamina was traced where visible. Grazing sections ofthe dermal- Table 2) . In four burn patients receiving placebo during both their first and second donor site healing periods, no significant differences could be shown between the first and the second healing times (Table 3) .
Electron Microscopy
No differences in keratinocyte size or differentiation were seen among treatment groups. Although the epider- Figure 2 .
Immunohistochemical Staining
Immunostaining for IGF-1 receptors showed cytoplasmic staining ofkeratinocytes. An increase in staining intensity, located in the mid epidermis of skin graft donor site biopsy, was observed during rhGH therapy (Fig.  3A) .
Immunostaining for laminin revealed relatively faint and discontinuous staining of the dermal-epidermal junction in biopsies of donor sites taken 7 days after grafting without growth factor treatment. There was a significant increase in laminin staining during rhGH treatment (Fig. 3B) . Staining for type IV collagen showed an increase in staining of the dermal-epidermal junction during rhGH treatment compared with placebo (Fig.  3C ).
Immunostaining for type VII collagen, a major component of the anchoring fibrils associated with the hemidesmosomes, which anchor the epidermis to the dermis, showed a distinct localization in the dermal-epidermal junction in uninjured skin. Faint and variable staining was seen in the biopsies without treatment taken 7 days after harvesting. Staining for type VII collagen increased in intensity after growth hormone treatment, although it still showed prominent variation in staining intensity along the junction, unlike the pattern seen in uninjured skin (Fig. 3D) .
Cytokeratin-14 is a relatively low molecular weight keratin species which, in the normal mature epidermis, is restricted in its expression to the basal cells. In all the biopsies examined, CK 14 was expressed in the keratinocytes of the middle layer of the epidermis with an increase in staining intensity observed during rhGH treatment (Fig. 3E) . In some cases, it was present in all the layers of the epidermis. This change may represent an alteration in the keratinocyte phenotype, with lack of differentiation, or specific differentiation toward the nor- earlier and more complete reformation of the structures necessary for dermal-epidermal attachment after growth hormone treatment. The components of the basement membrane zone chosen for study were laminin and type IV collagen, the principal components of the basal lamina; type VII collagen, the major component of the anchoring fibrils which extend from hemidesmosomes into the dermis; and cytokeratin 14, a keratin species associated with epidermal basal cells. Previous studies of wound healing in humans and animals have shown that the keratinocytes adjacent to the wound, whether on the surface or in follicles or glands, react rapidly by switching to a new phenotype characterized by motility and phagocytosis, with increased cell division occurring at some distance from the advancing front.21-25 The specialized attachment structures at the dermal-epidermal junction require several additional days to form, with expression of bullous pemphigoid antigen followed by type IV collagen and laminin, with formation of a basal lamina and hemidesmosomes.26'27 All the components of the basal lamina can be synthesized by wound keratinocytes, although the connective tissue cells of the matrix also may contribute. 28 Growth hormone may act directly through its own specific cell surface receptor to stimulate cell division or protein synthesis, may act by stimulating IGF-1 release from the liver into the circulation, or via paracrine or autocrine mechanisms at the injured site. 20 The junctional adhesion mechanism at the dermalepidermal junction includes hemidesmosomes, a basement membrane or basal lamina including a lamina lucida and a lamina densa, anchoring fibrils, and tonofilament bundles in epidermal basal cells. In this study, we measured the completeness of the newly formed basal lamina lining the basal cells of the epidermis and found it to be significantly more complete in the biopsies taken after growth hormone treatment. Laminin and type IV collagen are the major protein components ofthe lamina densa of the basal lamina,26 and both showed more intense staining after growth hormone treatment. Type VII collagen is the major component ofthe anchoring fibrils, which extend from the basal lamina at each hemidesmosome around the adjacent fibers of dermal (type I) collagen.4'42 This component of the junctional adhesion mechanism also showed more intense immunocytochemical staining after growth hormone treatment. The specimens from patients with the greatest improvement in wound healing time after growth hormone treatment also showed the greatest enhancement of immunostaining for laminin and for collagen types IV and VII. Taken together, these results indicate that growth hormone treatment accelerates the differentiation ofthe junctional mechanisms necessary for firm dermal-epidermal adhesion. Multiple cytokeratin types are synthesized by epidermal keratinocytes, and the pattern of expression changes as keratinocytes mature. Cytokeratin-14 is expressed exclusively by basal cells in the normal epidermis and constitutes a major protein component of the tonofilament bundles that attach to cell junctions and are thought to play a role in epithelial attachment.43"9 In all biopsies taken 7 days after harvesting a split-thickness skin graft, CK14 expression was seen most prominently in the mid epidermis, the zone that is thought to represent the proliferative compartment from which newly formed basal cells arise during wound healing.25 More CK 14 expression was seen in biopsies taken after growth hormone treatment. This represents enhanced production ofa protein that may have an important role in basal cell attachment.
In this study, biopsies taken from a second skin graft donor site, after treatment with growth hormone, consistently showed more complete differentiation of the dermal-epidermal junctional apparatus. We considered the possibility that improved healing of the second donor site might represent a nonspecific effect because of the patient's systemic responses to the burn injury, or to some aspect of the intensive care provided in the hospital, which may vary with time postburn. To examine this possibility, we studied biopsies taken according to the same protocol in four patients who did not receive growth hormone treatment during the healing phase of either the first or the second skin graft donor site. No differences were observed in the completeness of the newly formed basal lamina. Thus, the changes described here are thought to be effects of growth hormone treatment. It is possible that the changes observed may be secondary to stimulation of keratinocyte proliferation and more rapid re-epithelialization of the wound by growth hormone, allowing the processes ofdifferentiation to begin earlier. Cutaneous wound healing requires reconstitution ofthe dermal and the epidermal junction, and particularly the basement membrane for optimal skin strength and durability. Fibronectin, laminin and collagen Types I, IV and VII all play a role in achieving this wound healing. Dr. Herndon and his colleagues have elegantly documented these macromolecular elements and their enhancement when treated with growth hormone. Particularly impressive are the photomicrographs and immunostaining micrographs of donor site healing with and without growth hormone. The authors have postulated that the wound healing effects, like many of the anabolic effects ofgrowth hormone, are mediated by somatemedins, particularly IGF-1. One ofthe down sides to the use ofthis therapy is the potential for a hyperglycemic response which may limit its usefulness.
With those points in mind, I would like to ask Dr. Herndon the following questions:
Would you comment on the number ofpatients in this study who required exogenous insulin therapy? Since insulin and IGF-1 exert their anabolic effects through similar membrane receptors, do you believe that insulin could be a contributing factor to the results in this study? Do you believe that the same effects might be observed through the use of insulin alone, which is obviously much less costly?
Could you speculate on the apparent complete absence of improved donor site healing time among the three placebo-placebo patients? Though the growth hormone data is impressive, I am surprised that no improvement in healing time was observed for these patients in period 2, a time following definitive closure of much of the burn wound, when I would expect the nutritional balance to be much better.
And, finally, do you believe the introduction of growth factors in a topical fashion may exert a similar effect as that seen with the systemic effects of growth hormone? I raise this point because ofthe experience with cultured epithelial autografts in which these hormones are present in the nutrient media. Because of the inconsistent results with this therapy, one might postulate that the actual beneficial effects are from topical enhancement of wound healing through the growth factors in the media, rather than the cells themselves.
